Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
12 April 2021 |
Main ID: |
EUCTR2014-000253-36-GR |
Date of registration:
|
30/01/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Clinical Study to test the effect of the drug MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
|
Scientific title:
|
A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders. - A Double-masked, Placebo-controlled Study with Open label Period to Evaluate MEDI-551 in NMO/NMOSD |
Date of first enrolment:
|
31/03/2017 |
Target sample size:
|
212 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000253-36 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: Open label extension If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Bulgaria
|
Canada
|
Colombia
|
Czech Republic
|
Estonia
|
Germany
|
Greece
|
Hong Kong
|
Hungary
|
Israel
|
Japan
|
Korea, Republic of
|
Mexico
|
Moldova, Republic of
|
Netherlands
|
New Zealand
|
Peru
|
Poland
|
Portugal
|
Russian Federation
|
Serbia
|
South Africa
|
Spain
|
Taiwan
|
Thailand
|
Turkey
|
Ukraine
|
United States
| | | |
Contacts
|
Name:
|
Information Center
|
Address:
|
One MedImmune Way
MD 20878
Gaithersburg
United States |
Telephone:
|
13013980000 |
Email:
|
informationcenter@astrazeneca.com |
Affiliation:
|
MedImmune LLC |
|
Name:
|
Information Center
|
Address:
|
One MedImmune Way
MD 20878
Gaithersburg
United States |
Telephone:
|
13013980000 |
Email:
|
informationcenter@astrazeneca.com |
Affiliation:
|
MedImmune LLC |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1) Men and women 18 years or older with diagnosis of NMO/NMOSD.
2) Confirmation of NMO/NMOSD status:
a.) AQP4-IgG sero-positive NMO/NMOSD with at least one attack requiring rescue
therapy in the last year or two attacks requiring rescue therapy in the last 2 years.
b.) AQP4-IgG sero-negative NMO with at least one attack requiring rescue therapy in the
last year or two attacks requiring rescue therapy in the last 2 years.
3) Able and willing to give written informed consent and comply with the requirements of the study protocol.
4) EDSS <= 7.5 (8 in special circumstances).
5) Men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product.
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 200 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 12
Exclusion criteria: 1) Lactating and pregnant females.
2) Treatment with any investigational agent within 4 weeks of screening.
3) Known history of a severe allergy or reaction to any component of the investigational product formulation or history of anaphylaxis following any biologic therapy.
4) Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization.
5) History of of alcohol, drug, or chemical abuse, or a recent history of such abuse < 1 year prior to randomization.
6) Receipt of the following at any time prior to randomization:
a) Alemtuzumab
b) Total lymphoid irradiation
c) Bone marrow transplant
d) T-cell vaccination therapy
7) Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.
8) Receipt of IVIG within 1 month prior to randomization.
9) Receipt of any of the following within 3 months prior to randomization:
a) Natalizumab (Tysabri®)
b) Cyclosporin
c) Methotrexate
d) Mitoxantrone
e) Cyclophosphamide
f) Tocilizumab
g) Eculizumab
10) History of Hepatitis B and/or Hepatitis C (Hep B/C at screening).
11) Known history of a primary immunodeficiency (congenital or acquired) or an underlying condition such as human immunodeficiency virus (HIV) infection.
12) History of malignancies, apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months prior to randomization.
13) Any concomitant disease other than NMO/NMOSD that required treatment with oral or intravenous steroids at doses over 20 mg a day for over 21 days.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD) MedDRA version: 19.1
Level: LLT
Classification code 10029322
Term: Neuromyelitis optica
System Organ Class: 100000004852
|
Intervention(s)
|
Product Name: MEDI-551 Product Code: MEDI-551 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NA CAS Number: 1299440-37-1 Current Sponsor code: MEDI-551 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
|
Primary Outcome(s)
|
Primary end point(s): Time to an NMO/NMOSD attack determined by Adjudication Committee in randomized-control period
|
Timepoint(s) of evaluation of this end point: on or before Day 197
|
Main Objective: To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack
|
Secondary Objective: 1. To characterize the long-term efficacy of MEDI-551 by means of annualized attack rate. 2. To evaluate the safety and tolerability of MEDI-551 3. To characterize the pharmacokinetic (PK) profile and immunogenicity of MEDI-551
|
Secondary Outcome(s)
|
Secondary end point(s): 1. To characterize the long-term efficacy of MEDI-551 by means of annualized attack rate.
2. To evaluate the safety and tolerability of MEDI-551
3. To characterize the pharmacokinetic (PK) profile and immunogenicity of MEDI-551
|
Timepoint(s) of evaluation of this end point: End of Randomized-controlled Period and End of Study
|
Secondary ID(s)
|
NCT02200770
|
2014-000253-36-CZ
|
CD-IA-MEDI-551-1155
|
Source(s) of Monetary Support
|
MedImmune LLC
|
Ethics review
|
Status: Approved
Approval date: 31/03/2017
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|